Highlights

  • Archer finished the September 2026 quarter with A$13.0 million in cash and no Debt after raising fresh equity.
  • The company signed a three-year IonQ Quantum Compute Agreement on 1 July 2026, with payments totalling US$1.5 million.
  • A national Quantum Commercial Pilot invites Australian organisations to test computing problems on IonQ Forte Enterprise hardware.
  • Archer targets a structured Biochip trial with a leading US clinical research institution in Q4 FY27.

Archer Materials (ASX:AXE) has created a senior role to drive its Quantum Computing business, appointing David Vander as its inaugural Quantum Business Executive on 2 November 2026. Vander spent 16 years at Microsoft in senior global roles, including worldwide managing director for banking and financial services, and has served as chief executive of Avolution Software and ASX-listed LiveTiles.

He will lead quantum commercialisation and hardware development, with a remit to grow the Australian customer pipeline, deepen the company's Partnership with IonQ and advance next-generation graphene-based qubit hardware.

IonQ Partnership Becomes the Central Project

The appointment follows a three-year Quantum Compute Agreement with US-listed IonQ, signed on 1 July 2026 and renewable by mutual agreement. Archer pays US$250,000 on signing and every six months thereafter, totalling US$1.5 million, for access to the IonQ Quantum Cloud, including a Forte-class system, specialist engineering support and a framework to assess deploying an IonQ quantum computer in Australia.

On 14 September 2026, Archer launched a national Quantum Commercial Pilot, offering selected Australian businesses, government agencies, universities and start-ups complimentary compute time on IonQ Forte Enterprise hardware to test problems that are impractical for classical computers. Applications opened in October. Separately, a quantum Machine Learning Fraud detection project with CSIRO is due to deliver benchmark data in FY27, and the first financial services workshop with CSIRO was held on 28 October.

Fresh Capital Lifts the Cash Balance

Archer reported no Operating Revenue for FY26, the year to 30 June 2026, and a net loss after tax of A$6.36 million, an 8.8% improvement on FY25. Other income of A$2.84 million included an R&D tax incentive of A$2.35 million. Cash and deposits stood at A$8.42 million at 30 June.

After year end, the company completed a Placement Tranche of about A$6.86 million in July and a share purchase plan at A$0.27 a share that raised A$953,321 in August. In the September 2026 quarter, gross Equity proceeds were A$7.5 million and net operating cash outflow was A$2.78 million, leaving A$13.0 million in cash at 30 September.

Biochip and Qubit Milestones in FY27

The Biochip programme, which earlier showed silicon sensors matching graphene performance for blood potassium measurement, has completed multiple Beta prototype iterations. Archer targets delivering a prototype specification for external testing by mid-FY27, is in discussions with a leading US clinical research institution for a structured trial targeted in Q4 FY27, and is developing an Australian testing pathway with a Manufacturing partner.

On the hardware side, Archer said demonstrating a functional graphene spin qubit is taking longer than expected, although full-wafer manufacturing runs of refined designs were completed in FY26. The AGM is set for 20 November 2026 in Sydney. Shares were unchanged at A$0.175 on 2 November 2026, giving a Market Capitalisation of A$49.75 million, down 62.37% over 12 months.